Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have metastatic colorectal cancer that cannot be removed by surgery, with no prior treatment for advanced disease.
- Your tumor must be RAS and BRAF wild type (no mutations in these genes).
- You must be between 10 and 80 years old, or up to 85 if you are in good overall condition.
- You must have at least one measurable tumor that can be seen on scans.
- Your blood counts, liver and kidney function, and heart function must be within certain limits.
- You cannot have a type of tumor called MSI-H or dMMR.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different combinations of chemotherapy plus a targeted therapy called cetuximab as a first treatment for a specific type of advanced colorectal cancer. The goal is to see which combination works better and has fewer side effects.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a combination of two newer drugs plus chemotherapy as the first treatment for people with advanced colorectal cancer that has a RAS or BRAF gene change. The goal is to see if this combination helps shrink tumors and slow the cancer.
This trial tests a combination of two drugs (fruquintinib and adebrelimab) plus low or high dose radiation for people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Hear when a new Cetuximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.